Boston, MA – October [Date], 2026 – The vibrant biotech landscape of Boston is set to host a critical gathering of industry leaders this October as the 18th Annual Outsourcing in Clinical Trials (OCT) New England conference convenes. From October 27th to 28th, the biopharmaceutical sector will converge to dissect the most pressing challenges hindering the advancement of life-saving medical research, with the persistent and escalating struggle to recruit and retain participants emerging as the paramount concern. This year’s event underscores a growing realization within the industry that the very engine of clinical progress – patient involvement – is sputtering, threatening to derail promising therapeutic innovations.
The conference, a cornerstone event for stakeholders involved in the outsourcing of clinical trial activities, will dedicate significant attention to understanding the multifaceted nature of recruitment challenges and exploring actionable strategies to overcome them. From established pharmaceutical giants to emerging biotech innovators and contract research organizations (CROs), attendees will engage in robust discussions, share best practices, and forge collaborations aimed at revitalizing the clinical trial ecosystem.
The Recruitment Conundrum: A Deep Dive into the Core Challenge
At the heart of the OCT New England conference lies a critical examination of the global patient recruitment challenge. This issue, amplified by an unprecedented surge in therapeutic innovation, particularly in complex fields like oncology, has reached a tipping point. The sheer volume of novel drug candidates vying for patient participation is outstripping available resources, leading to alarming rates of trial termination due to insufficient enrollment.
The conference’s opening keynote will feature Kenneth Getz, a distinguished figure and Executive Director at the Tufts Center for the Study of Drug Development. Getz is poised to present compelling data that quantifies the global scale of this recruitment crisis, offering attendees a stark understanding of the problem’s magnitude. His insights will extend beyond mere quantification, delving into adaptive trial design strategies that sponsors can implement to better align with patient needs and accessibility. This will be followed by a high-level panel discussion, moderated by Getz himself, that will explore broader, systemic approaches to foster more agile and patient-centric trial designs. The emphasis will be on creating trials that are not only scientifically rigorous but also practically feasible for diverse patient populations.
The overarching sentiment is that the traditional models of patient recruitment are no longer sufficient. The increasing complexity of trial protocols, the rise of rare disease research, and the growing need for diverse representation among participants all contribute to a more demanding recruitment landscape. Experts at the conference will grapple with questions such as: How can we better identify and engage potential participants? What are the ethical considerations in reaching out to vulnerable populations? And how can technology be leveraged to streamline the recruitment process without compromising patient privacy and trust?
A Multifaceted Agenda: Navigating the Evolving Clinical Trial Landscape
Beyond the central theme of recruitment, the two-day conference will offer a comprehensive exploration of critical areas shaping the future of clinical trials. Sessions will be strategically divided into three distinct streams, ensuring a holistic approach to the industry’s challenges and opportunities:
- Outsourcing and Clinical Operations: This stream will delve into the intricate dynamics of managing outsourced clinical trial activities. Discussions will likely encompass vendor selection, performance management, and the evolving role of CROs in a rapidly changing regulatory and scientific environment. Emphasis will be placed on optimizing operational efficiency, ensuring data integrity, and navigating the complexities of global trial execution.
- Data, Artificial Intelligence (AI), and Clinical Innovation: This forward-looking stream will spotlight the transformative potential of data analytics and AI in accelerating drug discovery and development. Experts will explore how these technologies can be harnessed to improve trial design, enhance patient stratification, predict trial outcomes, and optimize operational processes. The ethical implications and practical challenges of integrating AI into clinical workflows will also be a key focus.
- Biotech Strategy: This stream will provide a platform for strategic discussions on the broader landscape of the biopharmaceutical industry. Topics will likely include navigating regulatory pathways, securing funding, fostering strategic partnerships, and adapting to market dynamics. The focus will be on equipping companies with the insights needed to thrive in an increasingly competitive and innovative sector.
Throughout these streams, talks will address pressing issues such as evolving regulatory frameworks, the growing imperative for patient-centricity in trial design, and the geopolitical factors that can influence global trial operations. Representatives from leading pharmaceutical companies and innovative vendors will share their perspectives, offering a rich tapestry of insights and experiences.
Voices from the Forefront: Industry Leaders Share Expertise
The conference will feature a distinguished roster of speakers, offering invaluable perspectives from various facets of the biopharma ecosystem. Aditya Kotta, Vice President of Business Development at Novotech, is slated to present on the latest clinical developments and market dynamics within both the US and Chinese markets, highlighting the increasing globalization of clinical research.
A particularly anticipated session will be an "Ask the Experts" panel featuring Akash Patel, Senior Director at GSK, and Vasudev Bhupathi, Director of Pharmacovigilance at Moderna. These seasoned professionals will provide guidance on the newly released International Council for Harmonisation (ICH) E6(R3) guidelines. This significant update to the Good Clinical Practice (GCP) guidelines is expected to usher in substantial changes to how clinical trials are designed, conducted, and reported, emphasizing a more risk-based and flexible approach. Understanding and implementing these new guidelines will be crucial for ensuring regulatory compliance and operational efficiency.
The AI Revolution in Clinical Trials: Opportunities and Pitfalls
Artificial Intelligence (AI) is poised to be a dominant theme throughout the conference, reflecting its growing influence on all aspects of clinical research. Kelly Butler, Ethics and Compliance Partner at Takeda Pharmaceutical, will lead an interactive session that tackles the critical issues of misrepresentation, bias, and the inherent limitations of data in AI-driven clinical insights. This discussion is vital for ensuring that the application of AI in clinical trials is both robust and ethically sound, preventing the propagation of errors or inequities.
Furthermore, a dedicated panel discussion, featuring representatives from Tufts, Novo, and Alnylam Therapeutics, will explore the evolving sponsor operating models. The conversation will focus on how organizations are adapting to seamlessly integrate AI into their workflows, moving towards more risk-based and centralized approaches to study monitoring. This shift is crucial for leveraging AI’s potential to enhance efficiency, identify potential issues earlier, and ultimately improve trial outcomes.
Day Two: Deepening Insights and Future-Gazing
The second day of the OCT New England conference will continue to explore crucial themes within the clinical trials space. Sessions will delve into practical applications of AI for study monitoring, offering attendees insights into how to leverage these technologies for more effective oversight. The critical decision of selecting the right Contract Research Organization (CRO) will also be a focal point, with discussions aimed at equipping attendees with the knowledge to make informed choices that align with their trial objectives and operational needs.
The conference will culminate with a keynote presentation by Kevin Bugin, Head of Global Regulatory Policy and Intelligence at Amgen. Bugin, a former Deputy Director of Operations at the U.S. Food and Drug Administration (FDA), brings a unique perspective from his extensive experience within the regulatory body. He is expected to outline how current FDA priorities are actively shaping the evolution of clinical progress, emphasizing a future characterized by greater speed, broader reach, and enhanced patient inclusivity. His insights will provide a vital outlook on the regulatory landscape and its impact on the trajectory of clinical development.
Implications and the Path Forward
The overwhelming focus on recruitment challenges at the 2026 OCT New England conference signals a critical juncture for the clinical trials industry. The ability to effectively recruit and retain participants is not merely an operational hurdle; it is a fundamental determinant of the pace at which new therapies reach patients. The discussions and resolutions emerging from this event will have profound implications for:
- Drug Development Timelines: Successful recruitment strategies can significantly shorten the time it takes to bring life-saving drugs to market, impacting patient access and public health. Conversely, persistent recruitment failures can lead to costly delays and the abandonment of promising research.
- Therapeutic Innovation: The explosion of innovation in areas like oncology and rare diseases hinges on the industry’s capacity to engage the right patient populations. Failure to do so could stifle progress in these critical therapeutic areas.
- Patient Centricity: The conference’s emphasis on patient-centric trial design reflects a broader industry trend towards prioritizing patient experience and engagement. This shift is not only ethically imperative but also strategically sound, as engaged patients are more likely to adhere to trial protocols.
- The Role of Technology: The integration of AI and data analytics is poised to revolutionize how trials are managed, from patient identification to data analysis. The conference will highlight both the immense potential and the critical ethical considerations associated with these advancements.
- The Outsourcing Landscape: The ongoing evolution of clinical trial operations necessitates a clear understanding of how to effectively partner with CROs and other vendors. Strategic outsourcing will be key to navigating complex global trials and optimizing resource allocation.
The 18th Annual Outsourcing in Clinical Trials New England conference stands as a vital platform for addressing the most significant challenges facing the biopharmaceutical industry today. By bringing together key stakeholders, fostering open dialogue, and sharing innovative solutions, the event aims to equip the industry with the strategies and insights necessary to overcome the critical recruitment hurdle and accelerate the delivery of transformative medical breakthroughs to patients worldwide.
A detailed agenda for the 18th Annual Outsourcing in Clinical Trials New England 2026 conference can be accessed here.
The conference is hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology.
Interested in attending or sponsoring Outsourcing in Clinical Trials? Complete the form below and the Arena team will be in touch.
About the Author
